Clinical Trial Update: Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

The document reports a Phase 3 clinical trial evaluating Anlotinib in combination with immunotherapy and chemoradiotherapy for high-risk nasopharyngeal carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Status: NOT_YET_RECRUITING